Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

Of the big oncology deals since 2016, there are still plenty that could go either way.

The 2024 AACR abstract title drop features several noteworthy clinical studies.

Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.

The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.

The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.